Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06347003 · ClinicalTrials.gov registry record · Phase 3

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

A Phase 3 study of Severe Hypertriglyceridemia, sponsored by Arrowhead Pharmaceuticals.

Active
Registry status
Phase 3
Development phase
446
Enrollment target
20
Study locations

NCT06347003 is a Phase 3 study of Severe Hypertriglyceridemia that is active but no longer recruiting, run by Arrowhead Pharmaceuticals. The registered enrollment target is 446 participants, above the 369-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target (21% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06347003, a Phase 3 study of Severe Hypertriglyceridemia, is active but no longer recruiting, sponsored by Arrowhead Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
446 participants
Enrollment target
20
Study locations

Study Summary

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.

Conditions Studied

Severe Hypertriglyceridemia

Interventions

  • DRUG Placebo
  • DRUG Plozasiran Injection

Study Locations (20)

Florida

  • Research Center 7 - Hialeah
  • Research Center 8 - Lake City
  • Research Center 9 - Miami Lakes
  • Research Center 10 - Mt. Dora
  • Research Center 11 - Orlando
  • Research Center 12 - Pensacola
  • Research Center 13 - Tamarac
  • Research Center 14 - Tampa

California

  • Research Center 1 - Garden Grove
  • Research Center 2 - Lake Forest
  • Research Center 3 - Montclair
  • Research Center 4 - Panorama City
  • Research Center 5 - Redding

Georgia

  • Research Center 15 - Macon
  • Research Center 16 - Savannah

Colorado

  • Research Center 6 - Colorado Springs

Illinois

  • Research Center 17 - Park Ridge

Louisiana

  • Research Center 18 - Eunice

Maryland

  • Research Center 19 - Baltimore

Michigan

  • Research Center 20 - Flint

Trial Details

FieldValue
Enrollment Target 446 participants
Start Date 2024-07-22
Est. Completion 2026-09
Phase Phase 3

Sponsor

Arrowhead Pharmaceuticals

15 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06347003

The ClinicalTrials.gov registry entry for NCT06347003 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 446 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 369-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target (21% higher). The listed sponsor is Arrowhead Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Severe Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06347003 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT06347003 about?

NCT06347003 is a clinical study titled "Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia". This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and...

What is the current status of trial NCT06347003?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 446 participants. The study started on 2024-07-22. Estimated completion is 2026-09.

What conditions does trial NCT06347003 study?

This clinical trial studies the following conditions: Severe Hypertriglyceridemia.

What interventions are being tested in trial NCT06347003?

The interventions under investigation include: Placebo (DRUG), Plozasiran Injection (DRUG).

Who is sponsoring clinical trial NCT06347003?

This trial is sponsored by Arrowhead Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06347003 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Severe Hypertriglyceridemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Severe Hypertriglyceridemia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.